Die Rolle Der Biomarker in Serum, Liquor Und Parenchym im Rahmen Der Aneurysmatischen Subarachnoidalblutung: Verlauf Und Korrelation zu Therapie Und Outcome - bioSAB -
试验速览
- 阶段
- 不适用
- 入组人数
- 310
- 试验地点
- 2
- 主要终点
- Biomarker in serum, cerebrospinal fluid and parenchyma after aneurysmal SAH
研究概览
简要总结
The aim of this study is to improve the usability of biomarkers for the timely prediction of new complications following a cerebral hemorrhage, especially in combination with invasive, functional and local measurements for patients with aneurysmal subarachnoid hemorrhage (SAH). Based on analyzed biomarker profiles the chosen therapy efforts are assessed in their immediate and longer-term effectiveness.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •male or female, age ≥ 18 years
- •signed consent for participation in the study
- •signed consent for further analysis of the samples collected during the clinical routine
- •in-patients
排除标准
- •female or male patient <18 years
- •pregnancy, lactation
- •lack of signed informed consent for participation in the study
- •lack of signed consent for the further analysis of the samples collected during the clinical routine
- •taking a study drug within the last thirty days
- •Simultaneous participation in another clinical trial (except participation as control group)
- •persons who are in a dependent relationship or employment with the sponsor or investigator
- •persons housed for a judicial or administrative order in an institution
结局指标
主要结局
Biomarker in serum, cerebrospinal fluid and parenchyma after aneurysmal SAH
时间窗: Each participant will be followed at hospital stay for an expected average of 3 weeks. The outcome measure will be assessed after 24 month.
Temporal development of alternative biomarkers in serum, cerebrospinal fluid and parenchyma after aneurysmal SAH, and their response as influenced by the treatment path.
次要结局
- Clinical outcome(Each participant will be followed at hospital stay for an expected average of 3 weeks. The outcome measure will be assessed after 24 month)
- Image morphological outcome(Each participant will be followed at hospital stay for an expected average of 3 weeks. The outcome measure will be assessed after 24 month)
研究者
Walid Albanna
Priv.-Doz. Dr. med. Walid Albanna
RWTH Aachen University